middle.news

Artrya Advances US Market Bid with FDA Filing for AI Coronary Plaque Module

8:57am on Monday 16th of June, 2025 AEST Healthcare
Read Story

Artrya Advances US Market Bid with FDA Filing for AI Coronary Plaque Module

8:57am on Monday 16th of June, 2025 AEST
Key Points
  • FDA 510(k) submission filed for Salix® Coronary Plaque module
  • Module enables near real-time detection of high-risk coronary plaque
  • Integration planned with FDA-cleared Salix® Coronary Anatomy platform
  • Qualifies for US reimbursement at US$950 per assessment upon clearance
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Artrya (ASX:AYA)
OPEN ARTICLE